Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RXRX NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$5.32-10.0%$5.07$3.79▼$12.36$2.31B0.9140.03 million shs59.52 million shsSDGRSchrodinger$19.08-7.6%$19.56$16.60▼$28.47$1.52B1.741.09 million shs1.02 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-9.98%-3.10%+17.18%+0.76%-13.50%SDGRSchrodinger-7.60%-7.33%+5.12%-9.19%+10.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$5.32-10.0%$5.07$3.79▼$12.36$2.31B0.9140.03 million shs59.52 million shsSDGRSchrodinger$19.08-7.6%$19.56$16.60▼$28.47$1.52B1.741.09 million shs1.02 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-9.98%-3.10%+17.18%+0.76%-13.50%SDGRSchrodinger-7.60%-7.33%+5.12%-9.19%+10.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRXRXRecursion Pharmaceuticals 2.17Hold$7.2536.28% UpsideSDGRSchrodinger 2.38Hold$26.2937.77% UpsideCurrent Analyst Ratings BreakdownLatest SDGR and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $28.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$19.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/27/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRXRXRecursion Pharmaceuticals$64.51M35.80N/AN/A$2.61 per share2.04SDGRSchrodinger$207.54M6.77N/AN/A$5.78 per share3.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)Latest SDGR and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025RXRXRecursion Pharmaceuticals-$0.35N/AN/AN/A$19.36 millionN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRXRXRecursion Pharmaceuticals0.023.583.58SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRXRXRecursion Pharmaceuticals89.06%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipRXRXRecursion Pharmaceuticals8.43%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableSDGR and RXRX HeadlinesRecent News About These CompaniesKeybanc Maintains Schrödinger (SDGR) Overweight RecommendationOctober 9 at 4:30 AM | msn.comSchrodinger (NASDAQ:SDGR) Price Target Lowered to $28.00 at KeyCorpOctober 8 at 9:23 AM | marketbeat.comSlow Capital Inc. Purchases New Shares in Schrodinger, Inc. $SDGROctober 7, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Receives $26.57 Consensus PT from AnalystsOctober 7, 2025 | americanbankingnews.comCraig-Hallum Keeps Their Buy Rating on Schrodinger (SDGR)October 4, 2025 | theglobeandmail.comSchrodinger (NASDAQ:SDGR) Downgraded to "Sell" Rating by Wall Street ZenOctober 4, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by AnalystsOctober 4, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Trading Down 3.6% - Here's WhyOctober 3, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Schrödinger (SDGR) with Neutral RecommendationOctober 1, 2025 | msn.comSchrodinger (NASDAQ:SDGR) Stock Rating Upgraded by The Goldman Sachs GroupOctober 1, 2025 | marketbeat.comPerigon Wealth Management LLC Purchases Shares of 14,636 Schrodinger, Inc. $SDGROctober 1, 2025 | marketbeat.comExpert Outlook: Schrodinger Through The Eyes Of 5 AnalystsOctober 1, 2025 | benzinga.comSchrodinger initiated with a Neutral at Goldman SachsSeptember 29, 2025 | msn.comWall Street Zen Upgrades Schrodinger (NASDAQ:SDGR) to "Hold"September 26, 2025 | marketbeat.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 18, 2025 | businesswire.comGoldman Sachs Group Inc. Sells 103,348 Shares of Schrodinger, Inc. $SDGRSeptember 16, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 2,737,728 Shares of Schrodinger, Inc. $SDGRSeptember 15, 2025 | marketbeat.comGeneos Wealth Management Inc. Boosts Position in Schrodinger, Inc. $SDGRSeptember 14, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Stock Price Down 5.9% - Should You Sell?September 12, 2025 | marketbeat.comJones Financial Companies Lllp Increases Stock Position in Schrodinger, Inc. $SDGRSeptember 12, 2025 | marketbeat.comSchrödinger (SDGR): Evaluating Valuation as Market Sentiment Remains QuietSeptember 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDGR and RXRX Company DescriptionsRecursion Pharmaceuticals NASDAQ:RXRX$5.32 -0.59 (-9.98%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$5.14 -0.18 (-3.38%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Schrodinger NASDAQ:SDGR$19.08 -1.57 (-7.60%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$18.90 -0.18 (-0.97%) As of 10/10/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
